A Study of Gastric Delay in Migraine Patients (3207-003)
- Registration Number
- NCT00548353
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Non-smoking male or female between 18 to 45 years of age
- Patient typically has between 2 and 10 migraine attacks per month, rated as moderate or severe
Exclusion Criteria
- Patient has any other medical conditions other than migraine
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 MK3207 MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
- Primary Outcome Measures
Name Time Method Safety in migraine patients 12 Weeks
- Secondary Outcome Measures
Name Time Method PK in migraine patients 12 Weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does MK3207 target to delay gastric emptying in migraine patients?
How does MK3207 compare to triptans in managing acute migraine attacks and interictal periods?
Are there specific biomarkers associated with improved pharmacokinetic outcomes in NCT00548353?
What adverse events were observed in the Phase 1 trial of MK3207 for migraine disorders and how were they managed?
What other compounds or combination therapies are being explored for gastric delay in migraine treatment by Merck Sharp & Dohme LLC?